Lilly, BI’s Jardiance still beats Novo’s Rybelsus when it comes to cost-effectiveness: ICER – FiercePharma

The Institute for Clinical and Economic Review (ICER) started giving Novo Nordisk a hard time about the cost-effectiveness of its oral version of semaglutide, Rybelsus, before the drug was even approved in September.
Now the product has its price tag $772 pe…

Click here to view the original article.